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CFA = cryptogenic fibrosing alveolitis; SEREX = serologic identification by recombinant expression cloning; Th = T-helper (cell).
Available online http://respiratory-research.com/content/2/2/061
Introduction
CFA is associated with inflammation and fibrosis of the
pulmonary interstitium and peripheral air spaces, and is
of unknown cause [1]. It is synonymous with the term
‘idiopathic pulmonary fibrosis’, which is employed in the
USA. Recent international consensus [2] defined this
entity more specifically, on the basis of the histopatho-
logical appearances of a usual interstitial pneumonia
pattern of idiopathic nature, thus distinguishing it from
usual interstitial pneumonia of known cause and from
idiopathic interstitial pneumonias with different
histopathological patterns.
Prevalence and incidence
The incidence has been estimated at 10.7 and 7.4 cases
per 100,000 for males and females, respectively, on the
basis of US registry data, whereas population-based
studies put the prevalence at between 3 and 20 cases per
100,000 [3]. Prognosis is generally poor, with mean sur-
vival from diagnosis of 3.2–5 years [4].
Aetiology
Potential aetiological risk factors for CFA include cigarette
smoking, and exposure to metal and wood dust [5–7].
Infectious agents, in particular Epstein–Barr virus, have
been implicated in case referent data that demonstrated
increased antibody titres to Epstein–Barr virus in CFA as
compared with pulmonary fibrosis of known causes [8],
although recent gene amplification studies [9,10] have
been equivocal. There is some evidence for hereditary
factors in descriptions of familial cases of CFA, although
these are infrequent, and there has been no clear demon-
stration of an association with the major histocompatibility
complex loci or other candidate genes.
Pathogenesis
The pathogenesis of CFA involves alveolar injury from an
unknown trigger, a persistent or repeated immuno-inflam-
matory phase, and dysregulated tissue repair, with exag-
gerated angiogenesis and fibroproliferation in susceptible
individuals. This results in progressive deposition of extra-
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cellular matrix, pulmonary fibrosis and lung destruction
[11]. These processes may run in parallel rather than
sequentially. Hence, the temporal pathological hetero-
geneity is reflected in the spatial heterogeneity of
histopathological appearances [12].
T-helper-1/T-helper-2 balance
The mechanisms that underlie the immunopathological
process are being elucidated. The balance of T-helper (Th)
lymphocyte subsets (Th1/Th2) appears important in this
respect. A Th2 response predominates in the pulmonary
interstitium of CFA. By contrast, Th1 and Th2 are equally
expressed in the lung of fibrosing alveolitis associated with
systemic sclerosis [13]. This may promote a profibrogenic
state, through the actions of fibroproliferative mediators
such as transforming growth factor-b, which is preferen-
tially expressed in the pulmonary epithelium and interstitium
of patients with CFA [14]. Moreover, the finding of reduced
expression of the Th1-derived cytokine interferon-g, which
may activate cell-mediated mechanisms for removal of cel-
lular antigens and restoration of normal tissue,  led to a
recent pilot study of interferon-g-1b in idiopathic pul-
monary fibrosis [15], with some reported outcome benefit.
Thus, fibrosis is believed to result from an imbalance
between proinflammatory and anti-inflammatory cytokines,
fibrogenic and antifibrogenic polypeptides, and angiogenic/
angiostatic molecules.
Autoantibodies
In CFA, polyclonal B-lymphocyte stimulation results in
increased peripheral blood immunoglobulin concentrations.
Non-organ-specific circulating autoantibodies have been
found in approximately 40% of patients with CFA [16].
These include antinuclear antibodies, anti-DNA topoiso-
merase II antibodies and antibodies to cytokeratin 8
[17–19]. Moreover, immune complexes are present in
blood, lung lavage fluid and tissue of CFA patients [20,21].
In seeking an explanation for the presence of autoantibod-
ies in CFA, it has been suggested that they are unlikely to
be a primary cause of tissue damage, although they may
augment the inflammatory process. It is possible that they
may represent a nonspecific consequence of lung inflam-
mation and injury, thereby providing some explanation for
their variable expression. More specific immunohistochemi-
cal data [22,23] have demonstrated the presence of circu-
lating IgG autoantibodies to pulmonary epithelial cells in
CFA patients, thus implicating the putative autoantigen as
endogenous and specific to the lung.
Public and private specificities: the core article
In the present issue of Respiratory Research, the interest-
ing report of Robinson et al [24] adds weight to the cir-
cumstantial evidence for an association between
autoantigens and CFA. Through the use of a cDNA library
derived from a tumour cell line, proteins were expressed,
and those recognized by antibodies that were present in
the serum of an index case were used to screen sera from
12 other patients with CFA. Three such autoantigens were
identified, of which alanyl tRNA synthetase has previously
been associated with pulmonary fibrosis in the context of
polymyositis, but not CFA. The absence of individual anti-
body specificities in more than one patient led to a conclu-
sion that these antibodies with so-called private
specificities in CFA sera are an epiphenomenona rather
than a potential cause of alveolar damage. The same
group used the serologic identification by recombinant
expression cloning (SEREX) technique to identify the
public antibody specificities that were present in patients
with malignant mesothelioma [25].
With regard to the study of Robinson et al [24] presented
in this issue, it is debatable whether a cloned malignant-
cell derived cDNA library can provide appropriate antigen
specificities to enable adequate identification of autoanti-
gens that are specifically relevant to CFA. Furthermore, a
single patient’s serum was used as the probe for the
expressed library, which makes subsequent screening
very dependent on the epitopic specificities of that individ-
ual’s (auto)immune response and of the origins of the
cloned library. Thus, there may be a potential under-repre-
sentation of autoantigens and their associated antibodies.
Therefore, although the private specificities identified in
the study of Robinson et al do not provide sufficient evi-
dence for a causative role in CFA, neither can this possi-
bility be ruled out on the basis of the small number of
patients screened and potential under-representation of
antigens from the cDNA library.
Conclusion
In conclusion, the pathogenesis of CFA remains unclear,
but involves a fibroblastic process that is coexistent with
or consequent upon a parenchymal injurious process. The
exact role of the autoantigen specificities that are identifi-
able in the sera of such patients is elusive. Do such
autoantibodies represent evidence of ongoing injury, or
could they be initiating the damaging process? Further-
more, could their presence amplify an already established
cycle of inflammation/fibrogenesis?
The presence of private specificities, which are frequently
associated with certain connective tissue/rheumatological
diseases, in serum from CFA (without clinical manifesta-
tions of an overlap state) is intriguing. Could CFA be a
‘local’ autoimmune process, and what additional molecular
process(es) is necessary for linking these autoantigens/
antibody complexes to a pulmonary inflammatory process
and the clinical manifestations of CFA/overlap syndromes.
With the use of new molecular techniques, including
SEREX, and with progress in well-defined cDNA library
technology, it is now possible to screen large numbers of
CFA sera. Perhaps the central ‘cause or effect’ questionc
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may then be addressed more rigorously. Genetic predis-
position and host susceptibility factor(s) that determine
the phenotypic expression of autoantibodies (as with Scl-
70 in systemic sclerosis) and clinical manifestations of
CFA remain unknown, and molecular genetic studies such
as that by Robinson et al are a welcome addition to our
present knowledge and must be commended. That report
points the way forward.
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